K2628
Ketotifen fumarate salt
≥99% (TLC), powder, H₁ histamine receptor antagonist
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C19H19NOS · C4H4O4
CAS Number:
Molecular Weight:
425.50
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
252-100-0
MDL number:
Form:
powder
Quality level:
Product Name
Ketotifen fumarate salt,
form
powder
Quality Level
originator
Novartis
SMILES string
OC(=O)\C=C\C(O)=O.CN1CCC(\CC1)=C2/c3ccccc3CC(=O)c4sccc24
InChI
1S/C19H19NOS.C4H4O4/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19;5-3(6)1-2-4(7)8/h2-5,8,11H,6-7,9-10,12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChI key
YNQQEYBLVYAWNX-WLHGVMLRSA-N
Gene Information
human ... HRH1(3269), PDE7B(27115)
General description
Ketotifen fumarate salt is an antihistamine drug.
Application
Ketotifen fumarate salt has been used: for mast cell product antagonism, as a positive control in β-hexosaminidase release assay, as mast cell stabilizer to treat pregnant dams added to ad libitum drinking water
Biochem/physiol Actions
H1 histamine receptor antagonist.
Ketotifen fumarate plays a key role in preventing histamine release by blocking the histamine H1 receptors. It interferes with the release of histamine, serotonin and other inflammatory mediators from mast cells. It exhibits with anti-allergic activity, anti-inflammatory effects including mast cell stabilization. It has been widely used for ophthalmic allergic conjunctivitis.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jeffrey KA
Side Effects of Drugs Annual (2005)
William L
Anabolics (2011)
Michael J Monument et al.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 61(4), 285-292 (2011-12-17)
Using a rabbit model of post-traumatic joint contractures, we investigated whether treatment with a mast cell stabilizer after joint injury would lessen the molecular manifestations of joint capsule fibrosis. Surgical joint injury was used to create stable post-traumatic contractures of